tbuckley/cabot-search huggingface dataset:
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Authors: David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak
Journal: Clinical Cancer Research (2018)

Abstract Purpose: This first-in-human, open-label phase I study evaluated AMG 337, an oral, highly selective small-molecule inhibitor of MET in advanced solid tumors. Patients and Methods: Patients enrolled into dose-escalation cohorts received AMG 337 up to 400 mg once daily or up to 250 mg twice daily, following a modified 3+3+3 design. Dose expansion was conducted in MET-amplified patients at the maximum tolerated dose (MTD). Primary endpoints included assessment of adverse events (AEs), establishment of the MTD, and pharmacokinetics; clinical response was a secondary endpoint. Results: The safety analysis set included 111 patients who received ≥1 dose of AMG 337. Thirteen patients had ≥1 AE qualifying as dose-limiting toxicity. The MTD was determined to be 300 mg once daily; the MTD for twice-daily dosing was not reached. Most frequent treatment-related AEs were headache (63%) and nausea (31%). Grade ≥3 treatment-related AEs occurred in 23 patients (21%), most commonly headache (n = 6) and fatigue (n = 5). Maximum plasma concentration occurred at 3.0 hours following 300-mg once-daily dosing, indicating AMG 337 absorption soon after treatment. Objective response rate was 9.9% (11/111; 95% CI, 5.1%–17.0%) in all patients and 29.6% (8/27; 95% CI, 13.8%–50.2%) in MET-amplified patients; median (range) duration of response was 202 (51–1,430+) days in all patients and 197 (64–1,430+) days in MET-amplified patients. Conclusions: Oral AMG 337 was tolerated with manageable toxicities, with an MTD and recommended phase II dose of 300 mg once daily. The promising response rate observed in patients with heavily pretreated MET-amplified tumors warrants further investigation. See related commentary by Ma, p. 2375
Cord‐serum per‐ and poly‐fluoroalkyl substances and atopy and eczema at 12‐months
Authors: Adrian J. Lowe, Shyamali C. Dharmage, Michael J. Abramson, Soumini Vijayasarathy, Bircan Erbas, Jochen F. Mueller, Caroline J. Lodge
Journal: Allergy (2018)
A phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer
Authors: S. Kitano, T. Shimizu, T. Koyama, T. Ebata, S. Iwasa, S. Kondo, A. Shimomura, Y. Fujiwara, N. Yamamoto, C. Baum, S. Li, P. Rietschel, T. Sims
Journal: Annals of Oncology (2018)
Abstract 16889: Ventricular Arrhythmia (VA) in Hypertrophic Cardiomyopathy (HCM): Novel Arrhythmia Risk Stratification Using T1 Mapping, Late Gadolinium Enhancement MRI (LGE-MRI), and Computational Modeling
Authors: Adityo Prakosa, Mark J Cartoski, Patrick M Boyle, Ryan P O'Hara, Farhad Pashakhanloo, Raffaele Coppini, Silvia Pradella, Stefan Zimmerman, M. Roselle Abraham, Niccolo Maurizi, Iacopo Olivotto, Natalia Trayanova
Journal: Circulation (2017)

Introduction: Current measures fail to precisely determine VA risk and implantable cardioverter defibrillator need in HCM patients. Emerging cardiac MRI-based tissue characterization methods and ne...
Impact of a Clinical Decision Support System on Guideline Adherence of Surveillance Recommendations for Colonoscopy After Polypectomy
Authors: Melissa Magrath, Edward Yang, Chul Ahn, Christian A. Mayorga, Purva Gopal, Caitlin C. Murphy, Samir Gupta, Deepak Agrawal, Ethan A. Halm, Eric K. Borton, Celette Sugg Skinner, Amit G. Singal
Journal: Journal of the National Comprehensive Cancer Network (2018)

Background: Surveillance colonoscopy is required in patients with polyps due to an elevated colorectal cancer (CRC) risk; however, studies suggest substantial overuse and underuse of surveillance colonoscopy. The goal of this study was to characterize guideline adherence of surveillance recommendations after implementation of an electronic medical record (EMR)-based Colonoscopy Pathology Reporting and Clinical Decision Support System (CoRS). Methods: We performed a retrospective cohort study of patients who underwent colonoscopy with polypectomy at a safety-net healthcare system before (n=1,822) and after (n=1,320) implementation of CoRS in December 2013. Recommendations were classified as guideline-adherent or nonadherent according to the US Multi-Society Task Force on CRC. We defined surveillance recommendations shorter and longer than guideline recommendations as potential overuse and underuse, respectively. We used multivariable generalized linear mixed models to identify correlates of guideline-adherent recommendations. Results: The proportion of guideline-adherent surveillance recommendations was significantly higher post-CoRS than pre-CoRS (84.6% vs 77.4%; P<.001), with fewer recommendations for potential overuse and underuse. In the post-CoRS period, CoRS was used for 89.8% of cases and, compared with cases for which it was not used, was associated with a higher proportion of guideline-adherent recommendations (87.0% vs 63.4%; RR, 1.34; 95% CI, 1.23-1.42). In multivariable analysis, surveillance recommendations were also more likely to be guideline-adherent in patients with adenomas but less likely among those with fair bowel preparation and those with family history of CRC. Of 203 nonadherent recommendations, 70.4% were considered potential overuse, 20.2% potential underuse, and 9.4% were not provided surveillance recommendations. Conclusions: An EMR-based CoRS was widely used and significantly improved guideline adherence of surveillance recommendations.
Plasma Glucose Level as a Predictor of In-Hospital Mortality in Patients at an Emergency Room: A Retrospective Cohort Study
Authors: Ryo Yoshinaga, Shizukiyo Ishikawa, Katsuhiko Ayukawa, Yasufumi Doi
Journal: Diabetes Care (2018)

A few studies have examined the association between plasma glucose (PG) levels of emergency room (ER) patients and their in-hospital mortality (1–3), but the threshold value of hypoglycemia at which the risk is increased has not been established. The objective of the current study was to investigate this issue.

A retrospective cohort study of ER patients and various risk factors for in-hospital death has been under way since 2014 at Iizuka Hospital (4), a teaching hospital with 1,048 beds located at the center of the Chikuho region of Fukuoka Prefecture on Japan's Kyushu Island. A detailed description of this survey has already been published (4). All 57,443 consecutive patients ≥18 years old who presented to Iizuka Hospital's ER by ambulance between 1 February 2006 and 30 September 2014 were evaluated. Among the 57,443 patients, 391 patients had repeated ER visits on two consecutive days; in those patients, only the index case was used, in order to comply with the assumption of independent observations. The 2,317 patients who experienced cardiopulmonary arrest, the 298 patients who were pregnant, and the 3,823 patients whose glucose level at baseline was not obtained were excluded. …
Maryland’s Hospital Global Budget Program
Authors: Eric T. Roberts, Ateev Mehrotra, Michael E. Chernew
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&amp;T in Metastatic Castration-resistant Prostate Cancer
Authors: Matthias M. Heck, Robert Tauber, Sebastian Schwaiger, Margitta Retz, Calogero D’Alessandria, Tobias Maurer, Andrei Gafita, Hans-Jürgen Wester, Jürgen E. Gschwend, Wolfgang A. Weber, Markus Schwaiger, Karina Knorr, Matthias Eiber
Journal: European Urology (2018)
Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults – A systematic review and meta-analysis
Authors: B. Pertzov, N. Eliakim-Raz, H. Atamna, A.Z. Trestioreanu, D. Yahav, L. Leibovici
Journal: Clinical Microbiology and Infection (2018)
Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis
Authors: Nicholas K. Mollanazar, May Elgash, Leslie Weaver, Rodrigo Valdes-Rodriguez, Sylvia Hsu
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Abstract 18972: Gender Differences in the Efficacy and Outcome of Atrial Fibrillation Ablation: Insights From the Kansai Plus Atrial Fibrillation (KPAF) Registry
Authors: Nobuaki Tanaka, Koichi Inoue, Satoshi Shizuta, Atsushi Kobori, Kazuaki Kaitani, Takeshi Morimoto, Toshiya Kurotobi, Itsuro Morishima, Kazuhiro Satomi, Hirosuke Yamaji, Yuko Nakazawa, Kengo Kusano, Koji Tanaka, Yuichi Ninomiya, Yuko Hirao, Takafumi Oka, Masato Okada, Ryo Nakamaru, Hiroyuki Inoue, Yasushi Koyama, Atsunori Okamura, Katsuomi Iwakura, Kenshi Fujii, Takeshi Kimura
Journal: Circulation (2017)

Introduction: There are significant differences in the prevalence and prognosis of cardiovascular diseases between men and women. Some previous studies have showed that catheter ablation (CA) for a...
Abstract 20382: Long-Term Follow-Up After NIRS Coronary Imaging: Insights From the ORACLE-NIRS Registry
Authors: Barbara A Danek, Aris Karatasakis, Phuong-Khanh J Nguyen-Trong, Judit Karacsonyi, Aya Alame, Erica Resendes, Pratik Kalsaria, Bavana Rangan, Michele Roesle, Shuaib Abdullah, Subhash Banerjee, Emmanouil Brilakis
Journal: Circulation (2016)

Introduction: Near-infrared spectroscopy (NIRS)-measured coronary lipid burden may be associated with the incidence of subsequent cardiovascular events. We sought to evaluate long-term outcomes aft...
Switching, Discontinuation, and Reinitiation of Statins Among Older Adults
Authors: Richard Ofori-Asenso, Jenni Ilomaki, Mark Tacey, Ella Zomer, Andrea J. Curtis, Si Si, Andrew R. Zullo, Maarit Jaana Korhonen, J. Simon Bell, Sophia Zoungas, Danny Liew
Journal: Journal of the American College of Cardiology (2018)
Immunologic reconstitution following hematopoietic stem cell transplantation despite lymph node paucity in NF-κB–inducing kinase deficiency
Authors: Khaoula Ben Farhat, Mohammed F. Alosaimi, Hiba Shendi, Suleiman Al-Hammadi, Jennifer Jones, Klaus Schwarz, Ansgar Schulz, Laila S. Alawdah, Sandra Burchett, Sultan Albuhairi, Jennifer Whangbo, Neha Kwatra, Hanan E. Shamseldin, Fowzan S. Alkuraya, Janet Chou, Raif S. Geha
Journal: Journal of Allergy and Clinical Immunology (2018)
Abstract 11141: Left Ventricular Global Longitudinal Strain in Patients With Heart Failure With Preserved Ejection Fraction: Outcomes Following an Acute Heart Failure Hospitalization
Authors: Jonathan Buggey, Fawaz Alenezi, Hyun Ju Yoon, Matthew Phelan, Adam D DeVore, Michel G Khouri, Phillip J Schulte, Eric J Velazquez
Journal: Circulation (2015)

Objectives: To assess the association between abnormal left ventricular global longitudinal strain (LV GLS) and outcomes in patients hospitalized with acute heart failure with preserved ejection fraction (HFpEF). Methods: Patients discharged alive from Duke University Medical Center between 2007 and 2010 following admission for acute HFpEF who had an echocardiogram with left ventricular ejection fraction ≥50% during the admission comprised the analysis cohort. We performed 2-dimensional, speckle-tracking analysis and stratified the cohort by LV GLS as normal (≤-16%) or abnormal (&gt;-16%). Cox proportional hazards models assessed the association between continuous LV GLS and outcomes. Results: We identified 545 consecutive patients with measurable LV GLS. The median LV GLS was -12.6% (25 th -75 th percentile, -15.5% to -10.6%) and 424 (78%) had abnormal LV GLS. Patients with abnormal LV GLS had higher levels of NT-proBNP (2548 vs. 1522 pg/mL, p=0.02) compared to those with normal LV GLS. There was no statistically significant association between LV GLS and mortality through 5 years (adjusted HR 1.02 per 1% increase; 95% CI: 0.98 to 1.06; p=0.33) or mortality and hospitalization (adjusted HR 1.02 per 1% increase; 95% CI: 0.99 to1.06; p=0.25) ( Figure ). A similar trend was seen between LV GLS and mortality and hospitalizations at 30 days (adjusted HR 1.08 per 1% increase; 95% CI: 1.00 to1.16; p=0.06) and 1 year (adjusted HR 1.04 per 1% increase; 95% CI: 1.00 to1.09; p=0.08). Conclusions: Using a cutoff value for LV GLS of -16%, a high prevalence of patients with acute HFpEF have abnormal LV GLS suggesting covert myocardial systolic dysfunction. However, LV GLS was not associated with mortality after accounting for traditional risk factors. Further studies are necessary to understand the role for LV GLS in routine clinical practice for HFpEF patients.
Abstract 15486: The Association of Susceptibility Genes of Abdominal Aortic Aneurysm and Atherosclerotic Cardiovascular Disease With Risk for All-cause Mortality
Authors: Zi Ye, Erin Austin, Adelaide M Arruda-Olson, Iftikhar J Kullo
Journal: Circulation (2015)

Introduction: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. The genetic contribution to mortality in patients with ASCVD is unknown. Hypothesis: Abdominal aortic aneurysm (AAA) often co-exists with ASCVD and two with shared genetic susceptibility underlying disease development. We hypothesiz that a genetic risk score (GRS) for susceptibility variants to AAA and ASCVD increases the risk for all-cause mortality in patients with ASCVD. Methods: We analyzed high-density genotyping data in 3053 participants (age 71 ±10 years, 72% men) with ASCVD in Mayo Vascular Disease Biorepository. We used 4 single nucleotide polymorphisms (SNPs) (rs2383207, rs7025486, rs599839, rs1466535) previously shown to be associated with AAA and ASCVD at GWAS significance (P ≤10^-8) in the NHGRI GWAS catalog to build the GRS. We defined ASCVD as a history of myocardial infarction / coronary revascularization / ischemic stroke / peripheral arterial disease with revascularization. Results: Patients with GRS &gt; median level had similar age (70±10 vs. 71±10), prevalence of men (72% vs. 73%), hypertension (83% vs. 82%), diabetes (32% vs. 31%) and smokers (74% vs. 72%) compared to those with GRS ≤ median (all P&gt;0.2), except for dyslipidemia (91% vs. 88%, P =0.02). After a median follow-up of 4.56 years (interquartile: 3.07-6.26), 620 patients died. Patients with GRS &gt; median had poorer survival compared to those with GRS ≤ median (Figure: Kaplan-Meier curve); and with 23% higher risk for death after adjustment for age, sex and cardiovascular risk factors (hazard ratio HR, 95% CI: 1.23, 1.05-1.45). The association of GRS with all-cause mortality remained significant after excluding patients with known AAA (n=672) (HR, 95%CI: 1.22, 1.01-1.48). Conclusions: A GRS for susceptibility variants of AAA and ASCVD is a prognostic marker in patients with ASCVD.
Gastrointestinal involvement in Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective case series
Authors: S. Gendreau, A. Amiot, Y. Le Baleur, C. Charpy, P. Wolkenstein, O. Chosidow, A. Mekontso Dessap, S. Ingen‐Housz‐Oro, N. Prost
Journal: British Journal of Dermatology (2018)
Preclinical safety and pharmacokinetic evaluation of Exherin™ (ADH-1) in Beagle dogs
Authors: Jan K. Losos, Robin J. Norris, William P. Peters
Journal: Cancer Research (2005)

4191  Exherin™ (ADH-1) is a cyclic pentapeptide molecule (N-Ac-CHAVC-NH2) being developed as a cell adhesion inhibitor of N-cadherin by interfering with the recognition sequence His-Ala-Val. Both in vitro and in vivo studies have confirmed the anti-tumor therapeutic potential of ADH-1. To evaluate the safety profile of this novel tumor vascular targeting agent, three GLP toxicity studies were conducted in Beagle dogs. In the first study, IV administration of ADH-1 at 1, 10, 50, 100, 250 and 500 mg/kg in dogs (1 dog/gender) revealed that the maximum tolerated dose exceeds 500 mg/kg, the highest dose tested. An intravenous dose escalation study was conducted to evaluate hemodynamic and cardiac function in conscious Beagle dogs (2 dogs/gender). Escalating ADH-1 doses of 5, 10, 50, and 100 mg/kg had no treatment-related effects on blood pressure, heart rate, cardiac parameters, or ECG. In the final study, toxicity and toxicokinetic parameters were evaluated for IV administration of 5, 10 and 50 mg/kg/day ADH-1 in Beagle dogs (3 dogs/gender/group) for 14 consecutive days of dosing. Blood samples for toxicokinetic analysis were collected on Day 1 and Day 14 at 0 (i.e. pre-dose), 0.033, 0.083, 0.167, 0.25, 0.5, 1, 4, and 8 hours post-dose. The AUC, t1/2, and Cmax increased with dose and at 10 and 50 mg/kg/day AUC and Cmax were slightly greater on Day 14 [AUC (ng.hr/ml)= 76525, Cmax (ng/ml)= 128707, t1/2 (hr)= 0.60] compared to Day 1 [AUC (ng.hr/ml)= 66693, Cmax (ng/ml)= 101382, t1/2 (hr)= 0.58]. Histopathology and ECG analysis after 14-days of ADH-1 treatment found no significant treatment-related pathology or gender-specific findings in any of the groups tested. In conclusion, ADH-1 was found to be well tolerated in Beagle dogs, without cardiovascular effects and satisfactory pharmacokinetics, and clinical evaluation is underway.
AB0483 Physicians’ awareness on the use of methotrexate by rheumatoid arthritis patients
Authors: B.N. Coskun, B. Yagiz, Y. Pehlivan, E. Dalkilic
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Methotrexate (MTX) is an anchor drug used in the treatment of rheumatoid arthritis (RA). It is notable that although MTX has severe potantial side effects, most of these side effects could be prevented. Patients should be informed very well regarding MTX and prescriptions should be prepared carefully. <h3>Objectives</h3> In this research, we sought to investigate patients with RA and also physicians, awareness regarding use of MTX, which is under-researched. <h3>Methods</h3> Following Fayet et al., the data were collected from rheumatoid arthritis patients (n=98) and physicians (n=82) through a questionnaire that included questions regarding the effects of MTX, MTX administration, drug interaction, side effects, the frequency of patient follow-up and changes regarding daily life. The questionnaire was filled by the patients in the hospital and physicians filled the on-line questionnaire. <h3>Results</h3> 23% patients responded correctly about that MTX is drug modifying antirheumatic drugs (DMARD). 88% of the patients stated that they used MTX weekly, only 16% of the patients were able to explain the reason why they used folic acid was reducing the toxicity of MTX and only 5% reported that folic acid did not increase the efficacy of MTX. 95% did not know that trimethoprim should not be combined with MTX. 11% were familiar with haematologic risks. 7% were aware of hypersensitivity pneumonitis. 42% had information regarding laboratory tests. 20% were concious concerning the need for contraception. 33% noted that alcohol consumption must be limited. The striking findings physicians responded wrongly was that according to 51% physicians, MTX leads to cancer. Surprisingly, approximately 30% physicians responded wrongly concerning surgery protocol. <h3>Conclusions</h3> The findings showed that patients with RA, who used MTX frequently, had insufficient information regarding MTX. Notably, patients are lack of information about the side effects of MTX, drug interactions and the need for contraception. Hence, we recommend that patients' knowledge should be increased regarding MTX. Physicians should be provided with training to raise awareness proper use of MTX. <h3>Reference</h3> [1] Fayet F, Savel C, Rodere M, et al. The development of a questionnaire to evaluate rheumatoid arthritis patient's knowledge about methotrexate. J Clin Nurs. 2016Mar;25(5–6):682–9. <h3>Acknowledgements</h3> We thank Jean-Jacques Dubost medical rheumatologist France for sharing the questionnaire that we used in this research. <h3>Disclosure of Interest</h3> None declared
Injection Drug Use-Associated Infective Endocarditis—Reply
Authors: Andrew Wang, Jeffrey G. Gaca, Vivian H. Chu
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer
Authors: J. Hasegawa, T. Kato, J. Nishimura, S. Yoshioka, S. Noura, Y. Kagawa, M. Yasui, M. Ikenaga, K. Murata, T. Hata, C. Matsuda, T. Mizushima, H. Yamamoto, Y. Doki, M. Mori
Journal: Annals of Oncology (2018)